EyeDNA Therapeutics' HORA─PDE6b gets US FDA rare pediatric disease designation for patients with retinal dystrophy due ...
EyeDNA Therapeutics, a wholly owned subsidiary of Coave Therapeutics and a clinical-stage gene therapy company, focused on developing life-changing therapeutics for inherited retinal disorders, announced that it has been granted a Rare Pediatric Disease …